Pneumococcal Conjugate Vaccine (PCV) market update
A market update providing information on the Pneumococcal Conjugate Vaccine (PCV) demand, supply and pricing trends.
UNICEF provides a market update for pneumococcal conjugate vaccine (PCV) highlighting demand, supply and pricing trends. UNICEF procures approximately 160 million doses of PCV annually on behalf of 60-70 countries globally. These include countries supported by Gavi, the Vaccine Alliance (Gavi), and those that fully self-finance their vaccine purchases. In part as a result of the Advance Market Commitment (AMC), the uptake in Gavi countries has accelerated, supply has stabilized, and prices have declined.
PCV supply through UNICEF is now available from three suppliers and is sufficient to meet current demand. Depending on the product/manufacturer, AMC tail prices for Gavi countries range between USD 2.00 and USD 3.30 per dose. UNICEF encourages self-financing middle-income countries to make multi-year demand commitments to access more affordable pricing. Looking ahead, UNICEF anticipates contracting a further one billion doses beyond 2020 through 2027 to cover new introductions and to sustain existing programmes.
Use the scroll down menu for previous versions of the document.